期刊文献+

江苏省阜宁地区自然人群中18~45岁女性人乳头瘤病毒16、18型中和抗体及DNA的流行率 被引量:4

Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu province
原文传递
导出
摘要 目的 研究江苏省阜宁地区自然人群中18~45岁女性人乳头瘤病毒(HPV)16、18型中和抗体及DNA的分布。方法 2012年12月至2013年1月,采用多阶段随机抽样的方法,在江苏省阜宁地区共招募1 494名18~45岁女性,采集宫颈脱落细胞进行HPV DNA检测,采集血清并通过假病毒中和试验检测抗HPV16、18型中和抗体,采用SPSS 21.0软件分析不同年龄段HPV DNA阳性率及HPV中和抗体阳性率的差异。结果 1 494名女性中HPV16型 DNA阳性28例(1.9%)、中和抗体阳性188例(12.6%);HPV18型 DNA阳性15例(1.0%)、中和抗体阳性60例(4.0%)。HPV16、18型 DNA和中和抗体阳性率在各年龄段的分布差异均无统计学意义(P〉0.05)。16.7%的研究对象已感染过HPV16和/或18型。结论 江苏省阜宁地区自然人群中18~45岁女性大多数未感染过HPV16、18型,是HPV16、18型疫苗应用的目标人群。 Objective To understand the distributions of DNA and neutralizing antibodies of human papillomavirus (HPV)16, 18 in 18-45 year-old women. Methods Totally, 1 494 women were enrolled through multistage random sampling in Funing, Jiangsu province. Cervical exfoliated cells were collected from them for HPV DNA testing, and serum samples were taken from them for the detection of HPV16, 18 neutralizing antibodies by using pseudovirion-based neutralization assay (PBNA). Results Among the 1 494 women, 28(1.9%) and 188(12.6%) were positive for DNA and neutralizing antibody of HPV16 respectively, and 15(1.0%) and 60(4.0%) were positive for DNA and neutralizing antibody of HPV18, respectively. There were no significant differences in the detection rates of DNA and neutralizing antibody of HPV16, 18 among different age groups. About 16.7% of the women were infected with HPV16, 18, or both. Conclusion In Funing county of Jiangsu province, most women aged 18-45 years has no immunity to HPV16 and 18, indicating that they are appropriate targets for HPV 16/18 vaccination.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2016年第3期406-409,共4页 Chinese Journal of Epidemiology
基金 福建省科技创新平台建设计划项目(2014Y2004)
关键词 人乳头瘤病毒 中和抗体 假病毒中和试验 基因型别 患病率 Human papillomavirus Neutralizing antibody Pseudovirion-based neutralization assay Genotype Prevalence
  • 相关文献

参考文献13

  • 1Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre) [R/OLd. Human Papillomavirus and Related Diseases in China. Summary Report, 2014 (2014-12-18) [2015-08-15]. https://www. hpvcentre.net/link_media/methodologies.pdf.
  • 2Schiller JT, Miiller M. Next generation prophylactic human papillomavirus vaccines [J]. Lancet Oncol, 2015, 16 (5) : e217- 225. DOI: 10.1016/S1470-2045( 14)71179-9.
  • 3MeCormack PL. Quadrivalent human papillomavirus (types 6, 11,16, 18) recombinant vaccine (gardasil) : a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts [J]. Drugs, 2014,74 ( 11 ) : 1253- 1283. DOI: 10.1007/s40265-014-O255-z.
  • 4Dai M, Bao YP, Li N, et al. Human papillomavirus infection in Shanxi Province, People' s Republic of China: a population- based study [J]. Br J Cancer, 2006, 95 (1) :96-101. DOI: 10. 1038/sj.bjc.6603208.
  • 5Li LK, Dai M, Clifford GM, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study [J]. Br J Cancer, 2006, 95 (11) : 1593- 1597. DOI: 10.1038/sj.bjc.6603450.
  • 6Zhao H, Lin Z J, Huang S J, et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination [J]. Hum Vaccin Immunother, 2014, 10 (3) : 740- 746. DOI: 10.4161/hv.27619.
  • 7de Sanjos6 S, Diaz M, Castellsagu6 X, et aL Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis [ J ]. Lancet Infect Dis, 2007,7 (7) : 453-459. DOI: 10.1016/S 1473-3099(07)70158-5.
  • 8Robbins HA, Kemp T J, Porras C, et al. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays [J]. Front Oncol, 2014, 3: 328. DOI: 10.3389/ fonc.2013.00328.
  • 9费满冬,李佳圆,杜旌畅,游嘉,张韶凯,何微,康乐妮,赵方辉,乔友林,司玉芝,樊小平,陈汶.子宫颈癌高危妇女中人乳头瘤病毒16和18型血清抗体分布特征[J].中华流行病学杂志,2014,35(5):514-518. 被引量:5
  • 10王建炳,胡尚英,王鹤,陈汶,马俊飞,苏采峰,李志霞,武燕萍,乔友林.山西农村地区妇女HPV-6、11、16、18的血清流行病学研究[J].中华微生物学和免疫学杂志,2009,29(8):701-705. 被引量:5

二级参考文献29

  • 1Parkin DM, Bray F. Chapter 2 : The burden of HPV-related cancers. Vaccine, 2006, 24 Suppl 3: S3/11-25.
  • 2de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology, 2004, 324( 1 ) : 17-27.
  • 3Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348(6) : 518-527.
  • 4Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 1998, 338(7) : 423-428.
  • 5Marais D, Rose RC, Lane C, et al. Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa. J Med Virol, 2000, 60 ( 3 ) : 331-336.
  • 6Di Bonito P, Grasso F, Mochi S, et al. Serum antibody response to human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, I2, FA, E6 and E7 proteins. Infect Agent Cancer, 2006, 1: 6.
  • 7Stone KM, Karem KL, Steinberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis, 2002, 186(10) : 1396-1402.
  • 8Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis, 2000, 181 (6): 1911- 1919.
  • 9Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk : nested case-control study. J Gen Virol, 2007, 88 ( Pt 3 ) : 814-822.
  • 10Michael KM, Waterboer T, Sehr P, et al Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog, 2008, 20; 4(6) : e1000091.

共引文献8

同被引文献33

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部